Angle Targets March For US FDA De Novo Submission
Following a Q-submission meeting with the US FDA, liquid biopsy firm Angle says it is in a strong position to progress a de novo submission for the Parsortix system by end of Q1.
You may also be interested in...
Angle Edges Closer To US FDA Clearance For Liquid Biopsy System
Angle is moving closer to becoming the first company to receive US FDA-clearance for a system that captures and harvests intact circulating tumor cells from patient blood for analysis.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.